wherein R_{11}, R_{12}, R_{13}, R_{14}, and R_{15}, independent of one another, are selected from the group consisting of hydrogen, halogen, nitro, alkyl, alkoxy and piperonyl.

39. The method of claim 35, wherein the medicament is selected from the group consisting of thiazide diuretics, metolazone, furosemide, bumetanide, ethacrynic acid, aldosterone antagonists, trimterene, and amiloride.

REMARKS

Claims 20 to 37, 39 to 51, 53, and 54 are pending. Claims 20 and 39 stand rejected. The Examiner indicated that claims 20 to 37, 39 to 51, 53, and 54 are free of the prior art of record. Applicants have amended claims 20 and 39. No new matter is presented.

Claims 20 and 39 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite. Specifically, claim 20 was dependent on canceled claim 1, and claim 39 was dependent on canceled claim 38. Applicants have amended claim 20 to incorporate the subject matter of canceled claim 1. In addition, Applicants have amended the numbering of the R groups of the second structure in claim 20 to clarify the R groups of the first and second chemical structures in the claim as amended. In addition, Applicants have amended claim 20 to contain proper Markush group language. Applicants have amended claim 39 to depend from claim 35. Accordingly, Applicants believe the basis for the rejection has been obviated and withdrawal of the rejection under 35 U.S.C. § 112, second paragraph is respectfully requested.

CONCLUSION

Applicants believe that in view of the amendments to the claims, and the remarks above, claims 20 to 37, 39-51, 53, and 54 are in condition for allowance. Such action is respectfully requested.

If the Examiner wishes to advance prosecution in any way, or if the Amendment is unclear, then the Examiner is invited to call the undersigned at the telephone number listed below.

Respectfully Submitted,

Chantal Morgan D'Apuzzo
Reg. No. 48,825
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617) 720-3500

Docket No. M00966.70001.US
Date: December 6, 2002
xxFebruary 5, 2003

MARKED-UP CLAIMS

20. An intermediate in the preparation of a [the] compound [of claim 1] comprising[:] a compound having the general structural formula:

Ar_1-X-Ar_2

wherein Ar_2 is an aryl group or a heteroaryl group, wherein the heteroaryl is a ring having 5, 6, or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, and which is substituted with R_1, R_2, R_3, R_4, and R_5;

wherein Ar_1 is an aryl group or a heteroaryl group, wherein the heteroaryl is a ring having 5, 6, or 7 atoms, and wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, and which is substituted with R_6, R_7, R_8, R_9, and R_{10};

wherein R_1, R_2, R_3, R_4, R_5, R_7, R_8, R_9, and R_{10} independent of one another, are selected from the group consisting of -H, halogen, piperonyl, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_1-C_6) alkoxy -CN, -OR', -SR', -NO_2, -NR'R', amino acid, -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR, -C(S)SR', -C(O)N(R')$_2$, -C(O)C(O)R', -C(S)C(O)R', -C(O)C(S)R', -C(S)C(S)R', -C(O)C(O)OR', -C(S)C(O)OR', -C(O)C(S)OR', -C(O)C(O)SR', -C(S)C(S)OR', -C(S)C(O)SR', -C(O)C(S)SR', -C(S)C(S)SR', -C(O)C(O)N(R')$_2$, -C(S)C(O)N(R')$_2$, -C(O)C(S)N(R')$_2$, or -C(S)C(S)N(R')$_2$;

wherein R_6 is in the ortho position and is selected from the group consisting of -CO-NH-(CH_2)$_{2\text{-}5}$$NH_2$, -CO-NH-($CH_2$)$_{2\text{-}5}$NH-($CH_2$)$_z$-H, -CO-NH($CH_2$)$_{2\text{-}5}$$NR_{15}$($CH_2$)$_z$-H, -CO-R', -CO-OR', -CO-SR', -CO-N(R')$_2$, -CO-CO-R', -CO-CS-R', -CO-CO-OR', -CO-CS-OR', -CO-CO-SR', -CO-CS-SR', -CO-CO-N(R')$_2$, -CO-CS-N(R')$_2$, -NH-CO-NH-(CH_2)$_{2\text{-}5}$$NH_2$, -NH-CO-NH-($CH_2$)$_{2\text{-}5}$NH-($CH_2$)$_z$-H, -NH-CO-NH($CH_2$)$_{2\text{-}5}$$NR_{15}$($CH_2$)$_z$-H, -NH-CO-R', -NH-CO-OR', -NH-CO-SR', -NH-CO-NO_2, -NH-CO-N(R')$_2$, -NH-CO-CO-R', -NH-CO-CS-R', -NH-CO-CO-OR', -NH-CO-CS-OR', -NH-CO-CO-SR', -NH-CO-CS-SR', -NH-CO-CO-N(R')$_2$, and -NH-CO-CS-N(R')$_2$,

wherein each R' is (CH_2)$_z$ -NR"R" and wherein R" is independently selected from the group consisting of (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkoxy, (C_1-C_6) alkynyl, (C_6-C_{20}) aryl, (C_6-C_{20}) substituted aryl, (C_6-C_{26}) alkaryl, substituted (C_6-C_{26}) alkaryl, and (C_5-C_7) heteroaryl wherein at least one atom of the heteroaryl is selected from the group consisting of a sulfur, a nitrogen, and an oxygen atom, wherein the aryl and alkaryl substituents are each independently selected from the group consisting of hydrogen, halogen, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl and trihalomethyl;

wherein z is 1-6;

wherein R_{15} is selected from the group consisting of halogen, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, and (C_1-C_6) alkoxy;

wherein X is a group having the following formula;

$-(CH_2)_m-Y-(CH_2)_n-$

wherein Y is selected from the group consisting of S, N, and O; and

wherein m and n, independent of one another, are integers of 0-5,

a compound having the general structural formula:



wherein [R_1, R_2, R_3, R_4, and R_5] R_{11}, R_{12}, R_{13}, R_{14}, and R_{15}, independent of one another, are selected from the group consisting of hydrogen, halogen, nitro, alkyl, alkoxy and [or] piperonyl.

39. The method of claim 35 [38], wherein the medicament is selected from the group consisting of thiazide diuretics, metolazone, furosemide, bumetanide, ethacrynic acid, aldosterone antagonists, trimterene, and amiloride.